Recent rulings from the Federal Circuit have provided important guidance on the issue of polymorph patent obviousness. As explored by Michael Green and John Molenda, these decisions delve deeply into the complexities of screening arguments, particularly emphasizing the notion of a reasonable expectation of success. Polymorphs, which are various crystalline forms an active pharmaceutical ingredient may assume, are pivotal in the lifecycle management strategy for innovator companies. This nuanced legal landscape is articulated through the lens of two Federal Circuit cases, offering valuable insight for legal professionals navigating similar challenges. The full analysis can be found at
Law360.